| ATTAIN | AIM | |||
| Abatacept + DMARDs n = 171 | Placebo + DMARDs n = 75 | Abatacept + MTX n = 351 | Placebo + MTX n = 155 | |
| Age, years | 52.5 (12.1) | 52.5 (12.0) | 50.8 (12.7) | 49.5 (11.6) |
| Gender, % female | 77.2 | 80.0 | 77.2 | 83.2 |
| Race, % Caucasian | 96.5 | 93.3 | 87.7 | 86.5 |
| Disease duration, years | 12.0 (8.1) | 11.7 (9.0) | 8.5 (7.1) | 8.9 (7.0) |
| Tender joints | 30.9 (13.4) | 31.0 (13.6) | 31.1 (12.8) | 33.7 (13.9) |
| Swollen joints | 22.6 (10.4) | 22.1 (10.1) | 21.3 (8.3) | 22.3 (8.3) |
| Erosion score* | N/A | N/A | 22.4 (18.3) | 22.1 (19.7) |
| Joint space narrowing score* | N/A | N/A | 23.3 (20.1) | 23.7 (21.3) |
| Total score* | N/A | N/A | 45.7 (37.4) | 45.8 (39.8) |
| Pain assessment, 100 mm VAS | 69.5 (20.5) | 68.0 (19.0) | 63.1 (21.1) | 67.3 (18.9) |
| Physical function, HAQ-DI | 1.8 (0.5) | 1.7 (0.6) | 1.7 (0.7) | 1.7 (0.6) |
| Patient global assessment, 100 mm VAS | 68.2 (19.6) | 66.7 (22.0) | 63.2 (20.9) | 63.8 (20.6) |
| Physician global assessment, 100 mm VAS | 67.7 (17.7) | 63.7 (18.2) | 69.3 (15.3) | 68.2 (15.9) |
| Levels of CRP, mg/dl | 4.4 (3.6) | 3.5 (3.3) | 3.3 (3.2) | 2.5 (2.1) |
| ESR, mm/h | 49.9 (27.7) | 43.7 (26.9) | 44.1 (23.5) | 43.0 (24.5) |
| DAS28 (CRP) | 6.5 (0.9) | 6.4 (0.8) | 6.4 (0.8) | 6.4 (0.8) |
| DAS28 (ESR) | 6.9 (1.0) | 6.8 (1.0) | 6.8 (0.9) | 6.9 (0.8) |
Data are mean (SD) unless otherwise stated.
*Values represent baseline readings for all patients with radiographic data at day 365 (n = 328 for abatacept; n = 137 for placebo).
AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; N/A, not applicable; VAS, visual analogue scale.